Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Sclerosis Relapse Clear all

Conditions: Multiple Sclerosis
Interventions: ARMS Questionnaire; Other
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Birmingham, Alabama • Oceanside, California • Hollywood, Florida + 2 more

Conditions: Non-relapsing Secondary Progressive Multiple Sclerosis
Interventions: Tolebrutinib, Placebo to match Tolebrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 1,131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 51
States / cities: Birmingham, Alabama • Phoenix, Arizona • Arcadia, California + 44 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Multiple Sclerosis
Interventions: AZD0120 - Regimen 1, AZD0120 - Regimen 2; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 5 more

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab, Placebo for Ocrelizumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 13
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Chicago, Illinois + 10 more

Conditions: Multiple Sclerosis
Interventions: MSDx Complex-1 Biomarker Test; Other
Lead sponsor: MSDx, Inc.; Industry
Eligibility: 45 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Relapsing Multiple Sclerosis
Interventions: Fenebrutinib, Teriflunomide, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 32
States / cities: Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 28 more

Conditions: Multiple Sclerosis
Interventions: Frexalimab, Teriflunomide, Placebo infusion, Placebo tablet, MRI contrast-enhancing agents, Cholestyramine, Activated charcoal; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,655 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 99
States / cities: Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 84 more

Conditions: Relapse Remitting Multiple Sclerosis
Interventions: Blood Draw; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Relapsing Multiple Sclerosis
Interventions: Ublituximab, Placebo, Fingolimod; Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Multiple Sclerosis
Interventions: Betaseron, Copaxone; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Natalizumab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 14
States / cities: Scottsdale, Arizona • Berkeley, California • Davis, California + 11 more

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Vatelizumab, Placebo (for Vatelizumab); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 9 more

Conditions: Multiple Sclerosis
Interventions: ONO-4641; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 20
States / cities: Tucson, Arizona • Aurora, Colorado • Fort Collins, Colorado + 17 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Autologous hematopoietic stem cell transplantation, Cyclophosphamide/ATG, Cyclophosphamide/Rituximab; Other · Drug
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 58 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Relapsing Multiple Sclerosis
Interventions: Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 821 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 40
States / cities: Phoenix, Arizona • Carmichael, California • La Jolla, California + 32 more

Conditions: Multiple Sclerosis
Interventions: Rebif; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: Dosing Interruption of Natalizumab; Drug
Lead sponsor: Berkovich, Regina MD, PhD Inc.; Other
Eligibility: 21 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: West Hollywood, California

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: natalizumab, dimethyl fumarate; Biological · Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 43
States / cities: Birmingham, Alabama • Cullman, Alabama • Gilbert, Arizona + 40 more

Conditions: Multiple Sclerosis
Interventions: ponesimod, teriflunomide; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 10
States / cities: Carlsbad, California • Pomona, California • Denver, Colorado + 7 more

Conditions: Multiple Sclerosis
Interventions: No Treatment Arm, Topical Preparation H arm; Other · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Pediatric Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 3 Years to 21 Years
Enrollment: 1,276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2018
U.S. locations: 17
States / cities: Birmingham, Alabama • San Bernardino, California • San Francisco, California + 13 more

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: dimethyl fumarate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 62
States / cities: Birmingham, Alabama • Tuscon, Arizona • Los Angeles, California + 57 more

Search by objective public record fields.

Assessing Relapse in Multiple Sclerosis (ARMS) Questionnaire

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)

Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)

Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis

Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY

Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS